Skip to Content

Copanlisib use while Breastfeeding

Drugs containing Copanlisib: Aliqopa

Medically reviewed by Drugs.com. Last updated on June 21, 2021.

Copanlisib Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of copanlisib during breastfeeding. Because copanlisib's half-life is about 39 hours, it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during copanlisib therapy and for 1 month after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Copanlisib

CAS Registry Number

1032568-63-0

Drug Class

  • Breast Feeding
  • Lactation
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Signal Transduction Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.